Yuko Palesch to Data Interpretation, Statistical
This is a "connection" page, showing publications Yuko Palesch has written about Data Interpretation, Statistical.
Connection Strength
1.906
-
Continuous covariate imbalance and conditional power for clinical trial interim analyses. Contemp Clin Trials. 2014 May; 38(1):9-18.
Score: 0.420
-
Covariate imbalance and adjustment for logistic regression analysis of clinical trial data. J Biopharm Stat. 2013; 23(6):1383-402.
Score: 0.387
-
Impact of safety monitoring on error probabilities of binary efficacy outcome analyses in large phase III group sequential trials. Pharm Stat. 2012 Jul-Aug; 11(4):310-7.
Score: 0.371
-
Treatment effect on ordinal functional outcome using piecewise multistate Markov model with unobservable baseline: an application to the modified Rankin scale. J Biopharm Stat. 2019; 29(1):82-97.
Score: 0.142
-
Assessing the impact of safety monitoring on the efficacy analysis in large Phase III group sequential trials with non-trivial safety event rate. J Biopharm Stat. 2016; 26(4):672-85.
Score: 0.114
-
Challenges of decision making regarding futility in a randomized trial: the Interventional Management of Stroke III experience. Stroke. 2014 May; 45(5):1408-14.
Score: 0.106
-
Measuring continuous baseline covariate imbalances in clinical trial data. Stat Methods Med Res. 2015 Apr; 24(2):255-72.
Score: 0.088
-
Quantifying the cost in power of ignoring continuous covariate imbalances in clinical trial randomization. Contemp Clin Trials. 2011 Mar; 32(2):250-9.
Score: 0.083
-
Using global statistical tests in long-term Parkinson's disease clinical trials. Mov Disord. 2009 Sep 15; 24(12):1732-9.
Score: 0.077
-
The impact of loss to follow-up on hypothesis tests of the treatment effect for several statistical methods in substance abuse clinical trials. J Subst Abuse Treat. 2009 Jul; 37(1):54-63.
Score: 0.073
-
An overview of the adaptive designs accelerating promising trials into treatments (ADAPT-IT) project. Ann Emerg Med. 2012 Oct; 60(4):451-7.
Score: 0.023
-
Flexible analytical methods for adding a treatment arm mid-study to an ongoing clinical trial. J Biopharm Stat. 2012; 22(4):758-72.
Score: 0.023